REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health has announced an upcoming investor webcast on April 30, 2025, at 8:30 AM Eastern to present initial results from a proof-of-concept study of crofelemer. The study focuses on two rare diseases: Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF).
The data was recently presented by Dr. Mohamad Miqdady at the 11th Annual ELITE PED-GI Congress in Abu Dhabi. The webcast will cover:
- Patient experience with MVID and SBS-IF
- Impact of crofelemer on disease progression
- Quality of life improvements
- Potential expedited regulatory pathways for MVID treatment
Notably, MVID is an ultrarare pediatric condition characterized by severe diarrhea and malabsorption, currently with no approved drug treatments. The study utilizes a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug.
Jaguar Health ha annunciato un webcast per investitori previsto il 30 aprile 2025 alle 8:30 AM Eastern, durante il quale presenterà i risultati iniziali di uno studio proof-of-concept su crofelemer. Lo studio riguarda due malattie rare: Microvillus Inclusion Disease (MVID) e Short Bowel Syndrome with Intestinal Failure (SBS-IF).
I dati sono stati recentemente presentati dal dott. Mohamad Miqdady all'11° Congresso Annuale ELITE PED-GI ad Abu Dhabi. Il webcast tratterà:
- L'esperienza dei pazienti con MVID e SBS-IF
- L'impatto di crofelemer sulla progressione della malattia
- Miglioramenti nella qualità della vita
- Possibili percorsi regolatori accelerati per il trattamento della MVID
È importante sottolineare che la MVID è una condizione pediatrica ultrarara caratterizzata da diarrea grave e malassorbimento, attualmente senza farmaci approvati. Lo studio utilizza una nuova formulazione liquida di crofelemer, il farmaco anti-secretorio a base vegetale di Jaguar Health.
Jaguar Health ha anunciado una próxima transmisión web para inversores el 30 de abril de 2025 a las 8:30 AM hora del Este, donde presentará los resultados iniciales de un estudio de prueba de concepto sobre crofelemer. El estudio se centra en dos enfermedades raras: Microvillus Inclusion Disease (MVID) y Short Bowel Syndrome with Intestinal Failure (SBS-IF).
Los datos fueron presentados recientemente por el Dr. Mohamad Miqdady en el 11º Congreso Anual ELITE PED-GI en Abu Dhabi. La transmisión cubrirá:
- La experiencia de los pacientes con MVID y SBS-IF
- El impacto de crofelemer en la progresión de la enfermedad
- Mejoras en la calidad de vida
- Posibles vías regulatorias aceleradas para el tratamiento de MVID
Es importante destacar que la MVID es una condición pediátrica ultrarrara caracterizada por diarrea severa y malabsorción, sin tratamientos farmacológicos aprobados actualmente. El estudio utiliza una novedosa formulación líquida de crofelemer, el medicamento anti-secretor de origen vegetal de Jaguar Health.
Jaguar Health는 2025년 4월 30일 동부시간 오전 8시 30분에 예정된 투자자 웹캐스트를 통해 크로펠러머(crofelemer)의 개념 증명 연구 초기 결과를 발표할 예정입니다. 이 연구는 두 가지 희귀 질환인 미세융모포함질환(MVID)과 장단축증후군 및 장부전증(SBS-IF)에 초점을 맞추고 있습니다.
이 데이터는 최근 아부다비에서 열린 제11회 ELITE PED-GI 연례 학술대회에서 모하마드 미크다디 박사에 의해 발표되었습니다. 웹캐스트에서는 다음 내용을 다룹니다:
- MVID 및 SBS-IF 환자의 경험
- 크로펠러머가 질병 진행에 미치는 영향
- 삶의 질 개선
- MVID 치료를 위한 신속한 규제 경로 가능성
특히 MVID는 심한 설사와 영양 흡수 장애를 특징으로 하는 초희귀 소아 질환으로, 현재 승인된 약물이 없습니다. 이 연구는 Jaguar의 식물성 항분비 처방약인 크로펠러머의 새로운 액상 제형을 사용합니다.
Jaguar Health a annoncé un webcast pour investisseurs prévu le 30 avril 2025 à 8h30, heure de l'Est, afin de présenter les résultats initiaux d'une étude de preuve de concept sur crofelemer. L'étude porte sur deux maladies rares : Microvillus Inclusion Disease (MVID) et Short Bowel Syndrome with Intestinal Failure (SBS-IF).
Les données ont été récemment présentées par le Dr Mohamad Miqdady lors du 11e congrès annuel ELITE PED-GI à Abu Dhabi. Le webcast abordera :
- L'expérience des patients atteints de MVID et de SBS-IF
- L'impact du crofelemer sur la progression de la maladie
- Les améliorations de la qualité de vie
- Les voies réglementaires potentielles accélérées pour le traitement de la MVID
Il est important de noter que la MVID est une maladie pédiatrique ultra-rare caractérisée par une diarrhée sévère et une malabsorption, sans traitement médicamenteux approuvé à ce jour. L'étude utilise une nouvelle formulation liquide de crofelemer, le médicament anti-sécrétoire d'origine végétale de Jaguar Health.
Jaguar Health hat eine bevorstehende Investoren-Webcast am 30. April 2025 um 8:30 Uhr Eastern angekündigt, bei der erste Ergebnisse einer Proof-of-Concept-Studie zu Crofelemer vorgestellt werden. Die Studie konzentriert sich auf zwei seltene Krankheiten: Microvillus Inclusion Disease (MVID) und Short Bowel Syndrome mit intestinalem Versagen (SBS-IF).
Die Daten wurden kürzlich von Dr. Mohamad Miqdady auf dem 11. ELITE PED-GI Jahreskongress in Abu Dhabi präsentiert. Der Webcast wird folgende Themen behandeln:
- Patientenerfahrungen mit MVID und SBS-IF
- Auswirkungen von Crofelemer auf den Krankheitsverlauf
- Verbesserungen der Lebensqualität
- Mögliche beschleunigte Zulassungswege für die MVID-Behandlung
Bemerkenswert ist, dass MVID eine ultrarare pädiatrische Erkrankung ist, die durch schwere Durchfälle und Malabsorption gekennzeichnet ist und derzeit keine zugelassenen Medikamente hat. Die Studie verwendet eine neuartige flüssige Formulierung von Crofelemer, dem pflanzenbasierten anti-sekretorischen verschreibungspflichtigen Medikament von Jaguar Health.
- Potential first-mover advantage as there are currently no approved drug treatments for MVID
- Study results presented by recognized leader in pediatric gastroenterology Dr. Mohamad Miqdady
- Novel liquid formulation of crofelemer being tested for two rare diseases (MVID and SBS-IF)
- Possible expedited regulatory pathways for crofelemer in MVID treatment
- Still in proof-of-concept phase, indicating early stage of development
- Results are from an investigator-initiated trial, not a company-sponsored pivotal study
- Actual efficacy data and trial results not disclosed in the press release
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study
SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today issued a reminder that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept investigator-initiated trial of a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates.
Participation Instructions for Jaguar Investor Webcast
When: Wednesday, April 30, 2025 at 8:30 AM Eastern Time
Where: Online
Registration link for conference: Click Here
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health/
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company will host an investor webcast on April 30, 2025. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What are the initial results of Jaguar Health's (JAGX) crofelemer study for MVID and SBS-IF?
What is MVID and why is Jaguar Health's (JAGX) crofelemer study significant?
When and where can investors join Jaguar Health's (JAGX) crofelemer study webcast?
What medical conditions does Jaguar Health's (JAGX) crofelemer target?
Who presented Jaguar Health's (JAGX) crofelemer study results at the ELITE PED-GI Congress?
